Published in Cancer Res on May 18, 2010
Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol (2011) 4.12
Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. J Clin Oncol (2015) 2.54
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A (2011) 2.35
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med (2013) 1.96
Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc Natl Acad Sci U S A (2011) 1.80
Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res (2012) 1.27
Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res (2014) 1.21
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res (2015) 1.18
NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy. Front Immunol (2015) 1.11
New paradigms for functional HIV-specific nonneutralizing antibodies. Curr Opin HIV AIDS (2013) 1.09
Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study. MAbs (2011) 1.08
A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy. Blood (2013) 1.03
Primary trastuzumab resistance: new tricks for an old drug. Ann N Y Acad Sci (2010) 1.03
Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology (2015) 0.99
Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein. Clin Cancer Res (2014) 0.99
Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy. Cell (2015) 0.99
Contribution of Human FcγRs to Disease with Evidence from Human Polymorphisms and Transgenic Animal Studies. Front Immunol (2014) 0.98
IgG-Fc glycoengineering in non-mammalian expression hosts. Arch Biochem Biophys (2012) 0.96
Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties. Breast Cancer Res (2011) 0.96
Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. World J Biol Chem (2012) 0.96
Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans. MAbs (2012) 0.95
Rapid high yield production of different glycoforms of Ebola virus monoclonal antibody. PLoS One (2011) 0.94
Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers. Br J Cancer (2011) 0.93
The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity. Cancer Biol Ther (2013) 0.92
Opportunities to exploit non-neutralizing HIV-specific antibody activity. Curr HIV Res (2013) 0.91
Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. Cancer Res (2012) 0.90
The emerging importance of α-L-fucose in human breast cancer: a review. Am J Transl Res (2011) 0.89
7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland. MAbs (2012) 0.88
Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant. MAbs (2013) 0.86
Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn. Br J Haematol (2014) 0.85
A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy. Oncotarget (2014) 0.84
Lepidopteran cells, an alternative for the production of recombinant antibodies? MAbs (2012) 0.83
Significant impact of single N-glycan residues on the biological activity of Fc-based antibody-like fragments. J Biol Chem (2012) 0.82
Physicochemical and biological characterization of a biosimilar trastuzumab. Biomed Res Int (2015) 0.82
Fc glycan-modulated immunoglobulin G effector functions. J Clin Immunol (2014) 0.82
PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. Clin Cancer Res (2015) 0.81
Improving natural killer cell cancer immunotherapy. Curr Opin Organ Transplant (2015) 0.80
Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells. MAbs (2012) 0.80
A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells. AMB Express (2016) 0.78
Microscale purification of antigen-specific antibodies. J Immunol Methods (2015) 0.77
A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy. Cancer Immun (2013) 0.76
Depletion of major pathogenic cells in asthma by targeting CRTh2. JCI Insight (2016) 0.76
Fc-Galactosylation of Human Immunoglobulin Gamma Isotypes Improves C1q Binding and Enhances Complement-Dependent Cytotoxicity. Front Immunol (2017) 0.75
Antitumor Efficacy of Anti-GD2 IgG1 Is Enhanced by Fc Glyco-Engineering. Cancer Immunol Res (2016) 0.75
Evaluation of treatment response for breast cancer: are we entering the era of "biological complete remission"? Chin J Cancer Res (2012) 0.75
Implications of understanding the signaling, cellular, and cytotoxic mechanisms afforded by afucosylated antibodies. Oncoimmunology (2015) 0.75
Pertuzumab to bolster Roche/Genentech's breast cancer franchise? Nat Biotechnol (2011) 0.75
Immunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies. Front Immunol (2016) 0.75
CHO-gmt5, a novel CHO glycosylation mutant for producing afucosylated and asialylated recombinant antibodies. Bioengineered (2012) 0.75
Cutting back on the carbs. Proc Natl Acad Sci U S A (2016) 0.75
Efficient In Vitro and In Vivo Activity of Glyco-Engineered Plant-Produced Rabies Monoclonal Antibodies E559 and 62-71-3. PLoS One (2016) 0.75
Role of Natural Killer Cells in HIV-Associated Malignancies. Front Immunol (2017) 0.75
Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics Syst Pharmacol (2017) 0.75
Rapid screening of IgG quality attributes - effects on Fc receptor binding. FEBS Open Bio (2017) 0.75
Glycome characterization of immunoglobulin G from buffalo (Bubalus bubalis) colostrum. Glycoconj J (2015) 0.75
Potent In Vivo NK Cell-mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-bispecific and Hexavalent Broadly Neutralizing Fusion Protein. J Virol (2017) 0.75
A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature (2012) 8.10
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell (2004) 6.12
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell (2009) 6.02
Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem (2002) 5.63
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol (2008) 5.54
Ubiquitin chain editing revealed by polyubiquitin linkage-specific antibodies. Cell (2008) 5.37
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res (2008) 5.34
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell (2003) 5.06
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell (2002) 4.34
Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol (2011) 4.12
VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature (2002) 4.10
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med (2007) 3.99
A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res (2008) 3.93
Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med (2002) 3.54
Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res (2006) 3.34
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol (2010) 3.06
Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol (2005) 3.00
Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell (2004) 2.60
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat (2010) 2.55
K11-linked polyubiquitination in cell cycle control revealed by a K11 linkage-specific antibody. Mol Cell (2010) 2.52
Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med (2011) 2.51
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol (2012) 2.43
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell (2011) 2.14
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell (2011) 2.14
Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med (2014) 2.07
Oncogenic ERBB3 mutations in human cancers. Cancer Cell (2013) 2.06
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol (2005) 1.99
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother (2005) 1.98
Engineering and structural characterization of a linear polyubiquitin-specific antibody. J Mol Biol (2011) 1.93
Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res (2013) 1.89
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest (2009) 1.89
Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem (2004) 1.88
Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J Immunol Methods (2002) 1.85
A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo. Sci Transl Med (2011) 1.75
Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci U S A (2007) 1.73
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res (2009) 1.70
Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol (2009) 1.66
Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res (2011) 1.66
Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res (2010) 1.63
PPM1H is a p27 phosphatase implicated in trastuzumab resistance. Cancer Discov (2011) 1.50
Improved quantitative mass spectrometry methods for characterizing complex ubiquitin signals. Mol Cell Proteomics (2010) 1.43
A strategy for risk mitigation of antibodies with fast clearance. MAbs (2013) 1.42
Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding. J Biol Chem (2004) 1.38
Tumor-driven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma. Clin Cancer Res (2006) 1.29
APRIL-deficient mice have normal immune system development. Mol Cell Biol (2004) 1.29
Preclinical studies with Erlotinib (Tarceva). Semin Oncol (2003) 1.29
Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res (2004) 1.29
Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression. Cancer Res (2007) 1.28
Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res (2012) 1.27
Tyrosine plays a dominant functional role in the paratope of a synthetic antibody derived from a four amino acid code. J Mol Biol (2005) 1.26
Death-receptor activation halts clathrin-dependent endocytosis. Proc Natl Acad Sci U S A (2006) 1.18
Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res (2012) 1.16
Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. J Biol Chem (2010) 1.15
Up-regulated expression of Ezrin and c-Met proteins are related to the metastasis and prognosis of gastric carcinomas. Histol Histopathol (2011) 1.14
Expression of Fas ligand and caspase-3 contributes to formation of immune escape in gastric cancer. World J Gastroenterol (2003) 1.11
Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies. J Mol Biol (2013) 1.11
Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood (2007) 1.09
A guide to rational dosing of monoclonal antibodies. Clin Pharmacokinet (2012) 1.08
BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding site. Biochemistry (2003) 1.08
Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association. J Biol Chem (2002) 1.07
Perspectives on anti-HER monoclonal antibodies. Oncology (2002) 1.06
Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res (2004) 1.06
Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Clin Cancer Res (2008) 1.04
High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity. PLoS One (2011) 1.03
Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells. Blood (2006) 1.02
Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer. Sci Transl Med (2013) 1.01
Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer. Clin Breast Cancer (2011) 1.01
Voltage-responsive vesicles based on orthogonal assembly of two homopolymers. J Am Chem Soc (2010) 1.01
Inhibiting alternative pathway complement activation by targeting the factor D exosite. J Biol Chem (2012) 1.01
Role of PTEN and MMP-7 expression in growth, invasion, metastasis and angiogenesis of gastric carcinoma. Pathol Int (2003) 0.99
Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab. J Mol Biol (2013) 0.98
Genetic analysis reveals that amyloid precursor protein and death receptor 6 function in the same pathway to control axonal pruning independent of β-secretase. J Neurosci (2014) 0.98
Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake. Mol Cancer Ther (2008) 0.98
Induction of Bv8 expression by granulocyte colony-stimulating factor in CD11b+Gr1+ cells: key role of Stat3 signaling. J Biol Chem (2012) 0.98
Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. J Pharmacokinet Pharmacodyn (2010) 0.97
Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci Transl Med (2013) 0.97
Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice. MAbs (2012) 0.96
Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. J Exp Med (2014) 0.96
PTEN encoding product: a marker for tumorigenesis and progression of gastric carcinoma. World J Gastroenterol (2003) 0.96
Significance and relationship between Yes-associated protein and survivin expression in gastric carcinoma and precancerous lesions. World J Gastroenterol (2009) 0.95
Variations of mitochondrial D-loop region plus downstream gene 1 2S rRNA-tRNA(phe) and gastric carcinomas. World J Gastroenterol (2003) 0.95
Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering. J Med Chem (2014) 0.95
Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge. MAbs (2014) 0.94
Loss of heterozygosity on 10q23.3 and mutation of tumor suppressor gene PTEN in gastric cancer and precancerous lesions. World J Gastroenterol (2005) 0.92
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol (2014) 0.92
Pathobiological behavior and molecular mechanism of signet ring cell carcinoma and mucinous adenocarcinoma of the stomach: a comparative study. World J Gastroenterol (2004) 0.92
Field-effect transistors based on few-layered α-MoTe(2). ACS Nano (2014) 0.91
Enzyme specific activation of benzoquinone ansamycin prodrugs using HuCC49DeltaCH2-beta-galactosidase conjugates. J Med Chem (2006) 0.90
Loss of heterozygosity and microsatellite instabilities of fragile histidine triad gene in gastric carcinoma. World J Gastroenterol (2006) 0.89
Overexpression of YAP1 is correlated with progression, metastasis and poor prognosis in patients with gastric carcinoma. Pathol Oncol Res (2014) 0.89
Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study. BMC Cancer (2012) 0.89